<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3463">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01379937</url>
  </required_header>
  <id_info>
    <org_study_id>115115</org_study_id>
    <nct_id>NCT01379937</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children</brief_title>
  <official_title>Safety and Immunogenicity Study of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine GSK1562902A in Children Aged 3 to 17 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Philippines: Food and Drug Administration Philippines</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and immunogenicity of a prime-boost
      schedule of GSK Biologicals' influenza vaccine in children aged 3 to 17 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study Influenza vaccine GSK1562902A is the primary study vaccine and Havrix™ will be
      administered as the active comparator and not co-administered along with the study
      vaccine.Therefore, there exist no relation between the vaccines administered in this study.
      As the study will be carried out in Philippines, Havrix™ vaccine will be used as an active
      comparator instead of saline placebo to offer an advantage to the subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Haemagglutination Inhibition (HI) Antibody Titers for the A/Turkey/Turkey/01/2005 (H5N1) Vaccine Strain.</measure>
    <time_frame>At Day 192.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antibody titers were expressed as Geometric mean titers (GMTs). The H5N1 vaccine strain included A/Turkey/Turkey/01/2005 antigen. The A/Turkey/Turkey/01/2005 (A/TURK) vaccine strain was administered to groups receiving the adjuvanted Influenza vaccine GSK1562902A. This outcome concerns solely subjects in the GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Any Medically Attended Adverse Events (MAEs)</measure>
    <time_frame>From Day 0 to Day 182</time_frame>
    <safety_issue>No</safety_issue>
    <description>Any = occurrence of the symptom regardless of intensity grade. This outcome concerns solely subjects in the GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Any Medically Attended Adverse Events (MAEs)</measure>
    <time_frame>From Day 0 to Day 364.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Any = occurrence of the symptom regardless of intensity grade.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>H5N1 HI Antibody Titres Against the A/Indonesia/5/2005 and A/Turkey/Turkey/01/2005 (H5N1 Virus) Strains</measure>
    <time_frame>At Days 0, 42, 182, 192, 364</time_frame>
    <safety_issue>No</safety_issue>
    <description>The antibody titres were given as Geometric Mean Titer (GMT). A/Indonesia/5/2005 = A/INDO and A/Turkey/Turkey/01/2005 = A/TURK.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>H5N1 HI Neutralizing Antibody Titres Against the A/Indonesia/5/2005 and A/Turkey/Turkey/01/2005 (H5N1 Virus) Strains</measure>
    <time_frame>At Days 0, 42, 182, 192, 364</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antibody titers were given as GMTs. A/Indonesia/5/2005 = A/INDO and A/Turkey/Turkey/01/2005 = A/TURK.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms.</measure>
    <time_frame>During a 7-day (Day 0-6) follow-up period after each vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</measure>
    <time_frame>During a 7-day (Day 0-6) follow-up period after each vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed solicited general symptoms were diarrhea/vomiting, drowsiness, irritability/fussiness, loss of appetite and temperature [defined as axillary temperature equal to or above 38 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. The symptoms were assessed for subjects aged less than 6 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</measure>
    <time_frame>During a 7-day (Day 0-6) follow-up period after vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia and temperature[defined as axillary temperature equal to or above 38 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. The symptoms were assessed for subjects aged 6 years or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</measure>
    <time_frame>During a 21-day (Days 0 - 20) follow-up period after vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</measure>
    <time_frame>During Day 0 to Telephone Contact (TC) Day 84 overall.</time_frame>
    <safety_issue>No</safety_issue>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Potential Immune-Mediated Diseases (pIMDs)</measure>
    <time_frame>During the entire study period (Day 0 to 364)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs).</measure>
    <time_frame>During the entire study period (Day 0 to 364)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-H5N1 Antibodies Above the Cut Off Values ≥1:10</measure>
    <time_frame>At Days 0, 42, 182, 192 and 364</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seropositivity rates against the A/Indonesia/5/2005 (H5N1 virus) strain, were tabulated on Days 0,42,182 for all subjects, 192 for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and 364 for GSK1562902A Formulation 1 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group.
Seropositivity rates against the A/turkey/Turkey/01/2005 (H5N1 virus) strain, were tabulated on Days 182, 192 and 364.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects Against the A/Indonesia/05/2005 Strains of H5N1 Influenza Disease</measure>
    <time_frame>At Days 42, 182, 192 and 364</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroconverted subject was defined as a vaccinee with either a pre-vaccination titer less than (&lt;) 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.
Seroconversion rates against the A/Indonesia/05/2005 (H5N1 VIRUS) strain were tabulated on Days 0,42,182 for all subjects, 192 for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and 364 for GSK1562902A Formulation 1 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects Against the A/Indonesia/05/2005 and A/Turkey/Turkey/01/2005 Strains of H5N1 Influenza Disease</measure>
    <time_frame>At Days 0,42, 182, 192 and 364</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection.
Seroprotection rates against the A/Indonesia/5/2005 (H5N1 virus) strain, were tabulated 95% CI on Days 0,42,182 for all subjects, 192 for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 -Havrix / Havrix Jr Group and 364 for GSK1562902A Formulation 1 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group.
Seroprotection rates against the A/turkey/Turkey/01/2005 (H5N1 virus) strain, were tabulated on Days 182 and 192.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Geometric Increase for Anti-H5N1 Antibody Titers</measure>
    <time_frame>At Days 42, 182, 192 and 364</time_frame>
    <safety_issue>No</safety_issue>
    <description>MGI against the A/Indonesia/05/2005 (H5N1 VIRUS) strain were tabulated on Days 0,42,182 for all subjects, 192 for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and 364 for GSK1562902A Formulation 1 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group.
MGI against the A/turkey/Turkey/01/2005 (H5N1 virus) strain were tabulated on Days 42, 182 and 364.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects Against the A/Turkey/Turkey/01/2005 Strains of H5N1 Influenza Disease</measure>
    <time_frame>At Days 192 and 364</time_frame>
    <safety_issue>No</safety_issue>
    <description>Booster seroconversion rates against the A/turkey/Turkey/01/2005 (H5N1 VIRUS) strain were tabulated on Days 192 and 364.
This outcome concerns solely subjects in the GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Booster Factor for Hemagglutination Inhibition (HI) Antibodies Against the A/Turkey/Turkey/01/2005 Strain of H5N1 Influenza Disease</measure>
    <time_frame>At Days 192 and 364</time_frame>
    <safety_issue>No</safety_issue>
    <description>Boooster factor against the A/turkey/Turkey/01/2005 (H5N1 VIRUS) strain were tabulated 95% CI on Days 192,364. This outcome concerns solely subjects in the GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Neutralizing Anti-H5N1 Antibody Titers</measure>
    <time_frame>At Days 0, 42, 182 192 and 364</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seropositivity rates against the A/Indonesia/5/2005 (H5N1 virus) strain, were tabulated on Days 0,42,182 for all subjects, 192 for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and 364 for GSK1562902A Formulation 1 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group.
Seropositivity rates against the A/turkey/Turkey/01/2005 (H5N1 virus) strain, were tabulated on Days 0, 42,182, 192 and 364.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Vaccine Response Rates (VRR) for H5N1 Neutralizing Antibodies</measure>
    <time_frame>At Days 42, 182 192 and 364</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Booster Vaccine Response for H5N1 Neutralizing Antibodies</measure>
    <time_frame>At Days 192 and 364</time_frame>
    <safety_issue>No</safety_issue>
    <description>This outcome concerns solely subjects in the GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">520</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Havrix / Havrix Jr Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccine GSK1562902A Formulation 1</intervention_name>
    <description>Intramuscular injection, two doses each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</description>
    <arm_group_label>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</arm_group_label>
    <arm_group_label>GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccine GSK1562902A Formulation 2</intervention_name>
    <description>Intramuscular injection, one dose each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</description>
    <arm_group_label>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</arm_group_label>
    <arm_group_label>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Havrix™</intervention_name>
    <description>Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group</description>
    <arm_group_label>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</arm_group_label>
    <arm_group_label>Havrix / Havrix Jr Group</arm_group_label>
    <arm_group_label>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</arm_group_label>
    <arm_group_label>GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Havrix™ Junior</intervention_name>
    <description>Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group,GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group</description>
    <arm_group_label>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</arm_group_label>
    <arm_group_label>Havrix / Havrix Jr Group</arm_group_label>
    <arm_group_label>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</arm_group_label>
    <arm_group_label>GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects must satisfy ALL the following criteria at study entry:

          -  Subjects for whom the investigator believes that the parent(s)/Legally Acceptable
             Representative(s) [LAR(s)] can and will comply with the requirements of the protocol
             .

          -  A male or female child 3 to 17 years of age inclusive, at the time of the first
             vaccination.

          -  Written informed consent obtained from the subject's parent or guardian. Assent
             obtained from the subject when applicable.

          -  Good general health as established by medical history and clinical examination before
             entering into the study.

          -  Comprehension by the subject's parent or guardian of the study requirements, ability
             to comprehend and comply with procedures for collection of short- and long-term
             safety data, expressed availability for the required study period, and ability and
             willingness to attend scheduled visits.

          -  Parent/LAR with access to a consistent means of telephone contact, land line or
             mobile, but NOT a pay phone or other multiple-user device (i.e., a common-use phone
             serving multiple rooms or apartments).

          -  Female subjects of childbearing potential may be enrolled in the study, if the
             subject:

               -  has practiced adequate contraception for 30 days prior to vaccination, and

               -  has a negative pregnancy test on the day of vaccination, and

               -  has agreed to continue adequate contraception during the entire treatment period
                  and for 2 months after completion of the vaccination series.

        Exclusion Criteria:

        The following criteria should be checked at the time of study entry. If ANY exclusion
        criterion applies, the subject must not be included in the study:

          -  Child in care

          -  Use of any investigational or non-registered product other than the study vaccine
             within 30 days preceding the first dose of the study vaccine or planned use during
             the study period.

          -  Planned administration of any vaccine 30 days prior and 21 days after any study
             vaccine administration.

          -  Active participation in other clinical trials.

          -  Receipt of systemic glucocorticoids within 1 month prior to study enrollment, or any
             other cytotoxic or immunosuppressive drug within 6 months of study enrollment.
             Topical, intra-articular or inhaled glucocorticoids are allowed.

          -  Acute disease and/or fever at the time of enrolment:

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition based on
             medical history and physical examination (no laboratory testing required).

          -  Acute or chronic, clinically-significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by medical history and physical examination.

          -  An acute evolving neurological disorder or history of Guillain-Barré syndrome within
             6 weeks of receipt of seasonal influenza vaccine.

          -  Receipt of any immunoglobulins and/or any blood products within 9 months of study
             enrolment or planned administration of any of these products during the study period.

          -  Any known or suspected allergy to any constituent of influenza vaccines ; a history
             of anaphylactic-type reaction to vaccine components or a history of severe adverse
             reaction to a previous influenza vaccine.

          -  History of seizures or progressive neurological disease.

          -  Pregnant or lactating female.

          -  Female planning to become pregnant or planning to discontinue contraceptive
             precautions.

          -  Diagnosed with cancer or any chronic severe disease.

          -  Previous administration of any H5N1 vaccine.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alabang, Muntinlupa</city>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1113</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>November 9, 2015</lastchanged_date>
  <firstreceived_date>June 17, 2011</firstreceived_date>
  <firstreceived_results_date>August 2, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza</keyword>
  <keyword>H5N1</keyword>
  <keyword>vaccine</keyword>
  <keyword>children</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study was of an overall duration 364 days for all subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</title>
          <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
        </group>
        <group group_id="P2">
          <title>GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</title>
          <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
        </group>
        <group group_id="P3">
          <title>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</title>
          <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
        </group>
        <group group_id="P4">
          <title>Havrix / Havrix Jr Group</title>
          <description>Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
                <participants group_id="P2" count="156"/>
                <participants group_id="P3" count="104"/>
                <participants group_id="P4" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="153"/>
                <participants group_id="P3" count="102"/>
                <participants group_id="P4" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</title>
          <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
        </group>
        <group group_id="B2">
          <title>GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</title>
          <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
        </group>
        <group group_id="B3">
          <title>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</title>
          <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
        </group>
        <group group_id="B4">
          <title>Havrix / Havrix Jr Group</title>
          <description>Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="156"/>
                <measurement group_id="B2" value="156"/>
                <measurement group_id="B3" value="104"/>
                <measurement group_id="B4" value="104"/>
                <measurement group_id="B5" value="520"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="9.70" spread="4.26"/>
                <measurement group_id="B2" value="9.40" spread="3.88"/>
                <measurement group_id="B3" value="9.3" spread="3.87"/>
                <measurement group_id="B4" value="9.6" spread="4.23"/>
                <measurement group_id="B5" value="9.51" spread="4.06"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="81"/>
                <measurement group_id="B2" value="81"/>
                <measurement group_id="B3" value="52"/>
                <measurement group_id="B4" value="52"/>
                <measurement group_id="B5" value="266"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="75"/>
                <measurement group_id="B2" value="75"/>
                <measurement group_id="B3" value="52"/>
                <measurement group_id="B4" value="52"/>
                <measurement group_id="B5" value="254"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Haemagglutination Inhibition (HI) Antibody Titers for the A/Turkey/Turkey/01/2005 (H5N1) Vaccine Strain.</title>
        <description>Antibody titers were expressed as Geometric mean titers (GMTs). The H5N1 vaccine strain included A/Turkey/Turkey/01/2005 antigen. The A/Turkey/Turkey/01/2005 (A/TURK) vaccine strain was administered to groups receiving the adjuvanted Influenza vaccine GSK1562902A. This outcome concerns solely subjects in the GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</description>
        <time_frame>At Day 192.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects (i.e., those meeting all eligibility criteria, complying with the procedures and intervals defined in the protocol, with no elimination criteria during the study) and for whom assay results were available for antibodies against the study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="127"/>
                  <measurement group_id="O2" value="84"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Haemagglutination Inhibition (HI) Antibody Titers for the A/Turkey/Turkey/01/2005 (H5N1) Vaccine Strain.</title>
            <description>Antibody titers were expressed as Geometric mean titers (GMTs). The H5N1 vaccine strain included A/Turkey/Turkey/01/2005 antigen. The A/Turkey/Turkey/01/2005 (A/TURK) vaccine strain was administered to groups receiving the adjuvanted Influenza vaccine GSK1562902A. This outcome concerns solely subjects in the GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</description>
            <units>Titer</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="737.6" lower_limit="646.8" upper_limit="841.1"/>
                  <measurement group_id="O2" value="24.7" lower_limit="19.7" upper_limit="31.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any Medically Attended Adverse Events (MAEs)</title>
        <description>Any = occurrence of the symptom regardless of intensity grade. This outcome concerns solely subjects in the GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</description>
        <time_frame>From Day 0 to Day 182</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the Total vaccinated Cohort, which included all subjects with at least 1 vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Formulation 1 &amp; 2 - Havrix/Havrix Jr Pooled Group</title>
            <description>Pooled group of subjects who received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, no or 1 booster dose of vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 or 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Formulation 2 - Havrix/Havrix Jr Pooled Group</title>
            <description>Pooled group of subjects who received no or 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="312"/>
                  <measurement group_id="O2" value="208"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any Medically Attended Adverse Events (MAEs)</title>
            <description>Any = occurrence of the symptom regardless of intensity grade. This outcome concerns solely subjects in the GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="115"/>
                  <measurement group_id="O2" value="64"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any Medically Attended Adverse Events (MAEs)</title>
        <description>Any = occurrence of the symptom regardless of intensity grade.</description>
        <time_frame>From Day 0 to Day 364.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the Total vaccinated Cohort, which included all subjects with at least 1 vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O4">
            <title>Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="156"/>
                  <measurement group_id="O2" value="156"/>
                  <measurement group_id="O3" value="104"/>
                  <measurement group_id="O4" value="104"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any Medically Attended Adverse Events (MAEs)</title>
            <description>Any = occurrence of the symptom regardless of intensity grade.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="65"/>
                  <measurement group_id="O2" value="84"/>
                  <measurement group_id="O3" value="41"/>
                  <measurement group_id="O4" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>H5N1 HI Antibody Titres Against the A/Indonesia/5/2005 and A/Turkey/Turkey/01/2005 (H5N1 Virus) Strains</title>
        <description>The antibody titres were given as Geometric Mean Titer (GMT). A/Indonesia/5/2005 = A/INDO and A/Turkey/Turkey/01/2005 = A/TURK.</description>
        <time_frame>At Days 0, 42, 182, 192, 364</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects (i.e., those meeting all eligibility criteria, complying with the procedures and intervals defined in the protocol, with no elimination criteria during the study) and for whom assay results were available for antibodies against the study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O4">
            <title>Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="155"/>
                  <measurement group_id="O2" value="152"/>
                  <measurement group_id="O3" value="103"/>
                  <measurement group_id="O4" value="101"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>H5N1 HI Antibody Titres Against the A/Indonesia/5/2005 and A/Turkey/Turkey/01/2005 (H5N1 Virus) Strains</title>
            <description>The antibody titres were given as Geometric Mean Titer (GMT). A/Indonesia/5/2005 = A/INDO and A/Turkey/Turkey/01/2005 = A/TURK.</description>
            <units>Titer</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>A/INDO, Day 0 [N=155,152,103,101]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.7" lower_limit="5.4" upper_limit="6.0"/>
                  <measurement group_id="O2" value="5.5" lower_limit="5.2" upper_limit="5.8"/>
                  <measurement group_id="O3" value="5.4" lower_limit="5.1" upper_limit="5.8"/>
                  <measurement group_id="O4" value="5.8" lower_limit="5.3" upper_limit="6.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 42 [N=155,152,103,101]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="553.5" lower_limit="490.9" upper_limit="624.1"/>
                  <measurement group_id="O2" value="595.0" lower_limit="522.1" upper_limit="678.2"/>
                  <measurement group_id="O3" value="5.6" lower_limit="5.2" upper_limit="6.0"/>
                  <measurement group_id="O4" value="6.2" lower_limit="5.6" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 182 [N=155,152,103,101]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52.2" lower_limit="47.7" upper_limit="57.1"/>
                  <measurement group_id="O2" value="54.1" lower_limit="49.5" upper_limit="59.1"/>
                  <measurement group_id="O3" value="5.1" lower_limit="5.0" upper_limit="5.2"/>
                  <measurement group_id="O4" value="5.6" lower_limit="5.3" upper_limit="6.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 192 [N=127,NA,45,NA]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="674.1" lower_limit="595.0" upper_limit="763.8"/>
                  <measurement group_id="O2" value="NA">For D192 , antibody titers were tabulated for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</measurement>
                  <measurement group_id="O3" value="7.6" lower_limit="6.7" upper_limit="8.5"/>
                  <measurement group_id="O4" value="NA">For D192 , antibody titers were tabulated for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 364 [N=151,147,100,NA]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="205.5" lower_limit="183.3" upper_limit="230.4"/>
                  <measurement group_id="O2" value="40.4" lower_limit="36.8" upper_limit="44.5"/>
                  <measurement group_id="O3" value="8.5" lower_limit="7.6" upper_limit="9.4"/>
                  <measurement group_id="O4" value="NA">For D364, antibody titers were tabulated for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group, GSK1562902A Formulation 1 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 0 [N=155,152,103,101]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="6.3" upper_limit="7.7"/>
                  <measurement group_id="O2" value="6.4" lower_limit="5.9" upper_limit="7.0"/>
                  <measurement group_id="O3" value="6.1" lower_limit="5.6" upper_limit="6.8"/>
                  <measurement group_id="O4" value="7.2" lower_limit="6.3" upper_limit="8.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 42 [N=155,152,103,101]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="193.0" lower_limit="172.1" upper_limit="216.5"/>
                  <measurement group_id="O2" value="240.3" lower_limit="188.1" upper_limit="240.3"/>
                  <measurement group_id="O3" value="6.9" lower_limit="6.9" upper_limit="7.9"/>
                  <measurement group_id="O4" value="8.5" lower_limit="7.2" upper_limit="10.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 182 [N=127,152,84,101]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39.6" lower_limit="35.8" upper_limit="43.8"/>
                  <measurement group_id="O2" value="42.5" lower_limit="38.9" upper_limit="46.4"/>
                  <measurement group_id="O3" value="6.0" lower_limit="5.5" upper_limit="6.5"/>
                  <measurement group_id="O4" value="7.0" lower_limit="6.1" upper_limit="8.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 364 [N=151,147,100,NA]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="215.1" lower_limit="190.3" upper_limit="243.3"/>
                  <measurement group_id="O2" value="35.4" lower_limit="32.2" upper_limit="39.0"/>
                  <measurement group_id="O3" value="18.4" lower_limit="16.3" upper_limit="20.9"/>
                  <measurement group_id="O4" value="NA">For D364, antibody titers were tabulated for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group, GSK1562902A Formulation 1 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>H5N1 HI Neutralizing Antibody Titres Against the A/Indonesia/5/2005 and A/Turkey/Turkey/01/2005 (H5N1 Virus) Strains</title>
        <description>Antibody titers were given as GMTs. A/Indonesia/5/2005 = A/INDO and A/Turkey/Turkey/01/2005 = A/TURK.</description>
        <time_frame>At Days 0, 42, 182, 192, 364</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects (i.e., those meeting all eligibility criteria, complying with the procedures and intervals defined in the protocol, with no elimination criteria during the study) and for whom assay results were available for antibodies against the study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O4">
            <title>Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="151"/>
                  <measurement group_id="O2" value="147"/>
                  <measurement group_id="O3" value="100"/>
                  <measurement group_id="O4" value="102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>H5N1 HI Neutralizing Antibody Titres Against the A/Indonesia/5/2005 and A/Turkey/Turkey/01/2005 (H5N1 Virus) Strains</title>
            <description>Antibody titers were given as GMTs. A/Indonesia/5/2005 = A/INDO and A/Turkey/Turkey/01/2005 = A/TURK.</description>
            <units>Titer</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>A/INDO, Day 0 [N=149,145,98,99]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.6" lower_limit="15.4" upper_limit="17.9"/>
                  <measurement group_id="O2" value="16.0" lower_limit="15.0" upper_limit="17.0"/>
                  <measurement group_id="O3" value="15.3" lower_limit="14.4" upper_limit="16.3"/>
                  <measurement group_id="O4" value="16.0" lower_limit="14.9" upper_limit="17.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO,Day 42 [N=150,146,99,100]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="726.8" lower_limit="646.1" upper_limit="817.6"/>
                  <measurement group_id="O2" value="804.1" lower_limit="710.8" upper_limit="909.5"/>
                  <measurement group_id="O3" value="15.3" lower_limit="14.4" upper_limit="16.4"/>
                  <measurement group_id="O4" value="17.0" lower_limit="15.1" upper_limit="19.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 182 [N=151,147,100,102]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="133.3" lower_limit="125.2" upper_limit="142.0"/>
                  <measurement group_id="O2" value="140.7" lower_limit="132.1" upper_limit="149.8"/>
                  <measurement group_id="O3" value="15.0" lower_limit="14.2" upper_limit="15.8"/>
                  <measurement group_id="O4" value="14.7" lower_limit="14.0" upper_limit="15.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 192 [N=149,NA,99,NA]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2128.0" lower_limit="1864.0" upper_limit="2429.5"/>
                  <measurement group_id="O2" value="NA">For D192 , antibody titers were tabulated for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</measurement>
                  <measurement group_id="O3" value="38.6" lower_limit="33.7" upper_limit="44.1"/>
                  <measurement group_id="O4" value="NA">For D192 , antibody titers were tabulated for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 364 [N=149,147,100,NA]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="523.1" lower_limit="452.9" upper_limit="604.2"/>
                  <measurement group_id="O2" value="132.7" lower_limit="123.9" upper_limit="142.2"/>
                  <measurement group_id="O3" value="30.4" lower_limit="26.8" upper_limit="34.4"/>
                  <measurement group_id="O4" value="NA">For D364, antibody titers were tabulated for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group, GSK1562902A Formulation 1 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 0, [N=149,145,98,100]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.4" lower_limit="15.3" upper_limit="17.6"/>
                  <measurement group_id="O2" value="15.9" lower_limit="15.0" upper_limit="16.9"/>
                  <measurement group_id="O3" value="15.6" lower_limit="14.5" upper_limit="16.8"/>
                  <measurement group_id="O4" value="17.3" lower_limit="15.8" upper_limit="19.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 42, [N=150,146,98,100]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="155.7" lower_limit="141.9" upper_limit="171.0"/>
                  <measurement group_id="O2" value="162.7" lower_limit="147.8" upper_limit="179.2"/>
                  <measurement group_id="O3" value="16.0" lower_limit="14.7" upper_limit="17.5"/>
                  <measurement group_id="O4" value="17.6" lower_limit="15.9" upper_limit="19.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 182, [N=151,147,100,101]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="85.3" lower_limit="79.7" upper_limit="91.2"/>
                  <measurement group_id="O2" value="85.1" lower_limit="79.2" upper_limit="91.3"/>
                  <measurement group_id="O3" value="15.7" lower_limit="14.6" upper_limit="16.8"/>
                  <measurement group_id="O4" value="15.5" lower_limit="14.5" upper_limit="16.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 192, [N=150,NA,100,NA]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1420.4" lower_limit="1229.6" upper_limit="1640.8"/>
                  <measurement group_id="O2" value="NA">For D192 , antibody titers were tabulated for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</measurement>
                  <measurement group_id="O3" value="68.3" lower_limit="58.2" upper_limit="80.2"/>
                  <measurement group_id="O4" value="NA">For D192 , antibody titers were tabulated for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 364, [N=149,145,98,NA]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="415.2" lower_limit="359.2" upper_limit="479.9"/>
                  <measurement group_id="O2" value="99.9" lower_limit="92.6" upper_limit="107.9"/>
                  <measurement group_id="O3" value="67.1" lower_limit="59.6" upper_limit="75.5"/>
                  <measurement group_id="O4" value="NA">For D364, antibody titers were tabulated for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group, GSK1562902A Formulation 1 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms.</title>
        <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.</description>
        <time_frame>During a 7-day (Day 0-6) follow-up period after each vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the Total vaccinated Cohort, which included all vaccinated subjects with at least 1 vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O4">
            <title>Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="156"/>
                  <measurement group_id="O2" value="156"/>
                  <measurement group_id="O3" value="104"/>
                  <measurement group_id="O4" value="104"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms.</title>
            <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Pain, D1 [N=156,156,104,104]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="112"/>
                  <measurement group_id="O3" value="45"/>
                  <measurement group_id="O4" value="43"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Pain, D1 [N=156,156,104,104]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Redness, D1 [N=156,156,104,104]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Redness, D1 [N=156,156,104,104]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Swelling, D1 [N=156,156,104,104]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Swelling, D1 [N=156,156,104,104]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Pain, D2 [N=156,156,104,103]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="93"/>
                  <measurement group_id="O2" value="103"/>
                  <measurement group_id="O3" value="65"/>
                  <measurement group_id="O4" value="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Pain, D2 [N=156,156,104,103]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Redness, D2 [N=156,156,104,103]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Redness, D2 [N=156,156,104,103]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Swelling, D2 [N=156,156,104,103]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Swelling, D2 [N=156,156,104,103]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Pain, D3 [N=156,154,0,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                  <measurement group_id="O2" value="52"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Pain, D3 [N=156,154,0,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Redness, D3 [N=156,154,0,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Redness, D3 [N=156,154,0,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Swelling, D3 [N=156,154,0,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Swelling, D3 [N=156,1540,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Pain, Across [N=156,156,104,104]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="127"/>
                  <measurement group_id="O2" value="129"/>
                  <measurement group_id="O3" value="73"/>
                  <measurement group_id="O4" value="53"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Pain, Across [N=156,156,104,104]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Redness, Across [N=156,156,104,104]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Redness, Across [N=156,156,104,104]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Swelling, Across [N=156,156,104,104]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="13"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Swelling, Across [N=156,156,104,104]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</title>
        <description>Assessed solicited general symptoms were diarrhea/vomiting, drowsiness, irritability/fussiness, loss of appetite and temperature [defined as axillary temperature equal to or above 38 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. The symptoms were assessed for subjects aged less than 6 years.</description>
        <time_frame>During a 7-day (Day 0-6) follow-up period after each vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on subjects aged less than 6 years, comprised in the Total vaccinated Cohort, which included all vaccinated subjects with at least 1 vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O4">
            <title>Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="22"/>
                  <measurement group_id="O4" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</title>
            <description>Assessed solicited general symptoms were diarrhea/vomiting, drowsiness, irritability/fussiness, loss of appetite and temperature [defined as axillary temperature equal to or above 38 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. The symptoms were assessed for subjects aged less than 6 years.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any diarrhoea/vomiting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 diarrhoea/vomiting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related diarrhoea/vomiting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any drowsiness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 drowsiness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related drowsiness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any irritability / fussiness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 irritability / fussiness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related irritability / fussiness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any loss of appetite</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 loss of appetite</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related loss of appetite</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any temperature</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 temperature</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related temperature</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</title>
        <description>Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia and temperature[defined as axillary temperature equal to or above 38 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. The symptoms were assessed for subjects aged 6 years or more.</description>
        <time_frame>During a 7-day (Day 0-6) follow-up period after vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on subjects aged 6 years or more, comprised in the Total vaccinated Cohort, which included all vaccinated subjects with at least 1 vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O4">
            <title>Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="126"/>
                  <measurement group_id="O2" value="125"/>
                  <measurement group_id="O3" value="82"/>
                  <measurement group_id="O4" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</title>
            <description>Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia and temperature[defined as axillary temperature equal to or above 38 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. The symptoms were assessed for subjects aged 6 years or more.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Arthralgia, D1 [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="20"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Arthralgia, D1 [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Arthralgia, D1 [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="19"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fatigue, D1 [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fatigue, D1 [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fatigue, D1 [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Gastrointestinal symptoms,D1 [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Gastrointestinal ,D1 [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Gastrointestinal ,D1 [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Headache, D1 [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="24"/>
                  <measurement group_id="O3" value="14"/>
                  <measurement group_id="O4" value="19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Headache, D1 [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Headache, D1 [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="23"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Myalgia, D1 [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="23"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Myalgia, D1 [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Myalgia, D1 [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="22"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Temperature/(Axillary), D1 [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Temperature/(Axillary),D1[N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Temperature/(Axillary),D1[N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Arthralgia, D2 [N=126,125,82,79]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="18"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Arthralgia, D2 [N=126,125,82,79]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Arthralgia, D2 [N=126,125,82,79]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="18"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fatigue, D2 [N=126,125,82,79]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fatigue, D2 [N=126,125,82,79]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fatigue, D2 [N=126,125,82,79]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Gastrointestinal symptoms, D2[N=126,125,82,79]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Gastrointestinal, D2 [N=126,125,82,79]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Gastrointestinal, D2 [N=126,125,82,79]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Headache, D2 [N=126,125,82,79]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="37"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Headache, D2 [N=126,125,82,79]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Headache, D2 [N=126,125,82,79]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="37"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Myalgia, D2 [N=126,125,82,79]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="20"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Myalgia, D2 [N=126,125,82,79]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Myalgia, D2 [N=126,125,82,79]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="19"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Temperature (Axillary), D2 [N=126,125,82,79]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Temperature(Axillary),D2 [N=126,125,82,79]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Temperature(Axillary),D2 [N=126,125,82,79]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="15"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Arthralgia, D3 [N=126,124,0,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Arthralgia, D3 [N=126,124,0,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Arthralgia, D3 [N=126,124,0,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fatigue, D3 [N=126,124,0,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fatigue, D3 [N=126,124,0,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fatigue, D3 [N=126,124,0,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Gastrointestinal, D3 [N=126,124,0,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Gastrointestinal, D3 [N=126,124,0,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Gastrointestinal, D3 [N=126,124,0,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Headache, D3 [N=126,124,0,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Headache, D3 [N=126,124,0,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Headache Headache, D3 [N=126,124,0,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Myalgia, D3 [N=126,124,0,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Myalgia, D3 [N=126,124,0,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Myalgia, D3 [N=126,124,0,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Temperature (Axillary), D3 [N=126,124,0,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Temperature (Axillary), D3 [N=126,124,0,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Temperature (Axillary), D3 [N=126,124,0,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Arthralgia, Across [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="11"/>
                  <measurement group_id="O4" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Arthralgia, Across [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Arthralgia, Across [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="30"/>
                  <measurement group_id="O3" value="11"/>
                  <measurement group_id="O4" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fatigue, Across [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="22"/>
                  <measurement group_id="O3" value="10"/>
                  <measurement group_id="O4" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fatigue, Across [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fatigue, Across [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="22"/>
                  <measurement group_id="O3" value="10"/>
                  <measurement group_id="O4" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Gastrointestinal, Across [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Gastrointestinal, Across [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Gastrointestinal, Across [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Headache, Across [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="63"/>
                  <measurement group_id="O2" value="52"/>
                  <measurement group_id="O3" value="20"/>
                  <measurement group_id="O4" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Headache, Across [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Headache, Across [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="62"/>
                  <measurement group_id="O2" value="51"/>
                  <measurement group_id="O3" value="18"/>
                  <measurement group_id="O4" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Myalgia, Across [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="13"/>
                  <measurement group_id="O4" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Myalgia, Across [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Myalgia, Across [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="13"/>
                  <measurement group_id="O4" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Temperature/(Axillary),Across[N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="19"/>
                  <measurement group_id="O3" value="10"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Temperature, Across [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Temperature, Across [N=126,125,82,80]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
        <time_frame>During a 21-day (Days 0 – 20) follow-up period after vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects with at least 1 vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O4">
            <title>Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="156"/>
                  <measurement group_id="O2" value="156"/>
                  <measurement group_id="O3" value="104"/>
                  <measurement group_id="O4" value="104"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</title>
            <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="82"/>
                  <measurement group_id="O3" value="35"/>
                  <measurement group_id="O4" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="NA">Grade 3 AEs were not reported in this group.</measurement>
                  <measurement group_id="O4" value="NA">Grade 3 AEs were not reported in this group.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
        <time_frame>During Day 0 to Telephone Contact (TC) Day 84 overall.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects with at least 1 vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O4">
            <title>Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="156"/>
                  <measurement group_id="O2" value="156"/>
                  <measurement group_id="O3" value="104"/>
                  <measurement group_id="O4" value="104"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</title>
            <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="75"/>
                  <measurement group_id="O2" value="92"/>
                  <measurement group_id="O3" value="59"/>
                  <measurement group_id="O4" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Potential Immune-Mediated Diseases (pIMDs)</title>
        <time_frame>During the entire study period (Day 0 to 364)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects with at least 1 vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O4">
            <title>Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="156"/>
                  <measurement group_id="O2" value="156"/>
                  <measurement group_id="O3" value="104"/>
                  <measurement group_id="O4" value="104"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any Potential Immune-Mediated Diseases (pIMDs)</title>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs).</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>During the entire study period (Day 0 to 364)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects with at least 1 vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O4">
            <title>Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="156"/>
                  <measurement group_id="O2" value="156"/>
                  <measurement group_id="O3" value="104"/>
                  <measurement group_id="O4" value="104"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Serious Adverse Events (SAEs).</title>
            <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-H5N1 Antibodies Above the Cut Off Values ≥1:10</title>
        <description>Seropositivity rates against the A/Indonesia/5/2005 (H5N1 virus) strain, were tabulated on Days 0,42,182 for all subjects, 192 for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and 364 for GSK1562902A Formulation 1 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group.
Seropositivity rates against the A/turkey/Turkey/01/2005 (H5N1 virus) strain, were tabulated on Days 182, 192 and 364.</description>
        <time_frame>At Days 0, 42, 182, 192 and 364</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects (i.e., those meeting all eligibility criteria, complying with the procedures and intervals defined in the protocol, with no elimination criteria during the study) and for whom assay results were available for antibodies against the study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O4">
            <title>Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="155"/>
                  <measurement group_id="O2" value="152"/>
                  <measurement group_id="O3" value="103"/>
                  <measurement group_id="O4" value="101"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Anti-H5N1 Antibodies Above the Cut Off Values ≥1:10</title>
            <description>Seropositivity rates against the A/Indonesia/5/2005 (H5N1 virus) strain, were tabulated on Days 0,42,182 for all subjects, 192 for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and 364 for GSK1562902A Formulation 1 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group.
Seropositivity rates against the A/turkey/Turkey/01/2005 (H5N1 virus) strain, were tabulated on Days 182, 192 and 364.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/INDO, Day 0 [N=155,152,103,101]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="15"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 42 [N=155,152,103,101]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="155"/>
                  <measurement group_id="O2" value="151"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 182 [N=155,152,103,101]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="154"/>
                  <measurement group_id="O2" value="152"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 192 [N=127,0,84,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="127"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="37"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 364 [N=151,147,100,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="151"/>
                  <measurement group_id="O2" value="147"/>
                  <measurement group_id="O3" value="57"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 182 [N=127,152,84,101]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="126"/>
                  <measurement group_id="O2" value="152"/>
                  <measurement group_id="O3" value="17"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 364 [N=151,147,100,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="151"/>
                  <measurement group_id="O2" value="147"/>
                  <measurement group_id="O3" value="95"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects Against the A/Indonesia/05/2005 Strains of H5N1 Influenza Disease</title>
        <description>A seroconverted subject was defined as a vaccinee with either a pre-vaccination titer less than (&lt;) 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.
Seroconversion rates against the A/Indonesia/05/2005 (H5N1 VIRUS) strain were tabulated on Days 0,42,182 for all subjects, 192 for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and 364 for GSK1562902A Formulation 1 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group.</description>
        <time_frame>At Days 42, 182, 192 and 364</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects (i.e., those meeting all eligibility criteria, complying with the procedures and intervals defined in the protocol, with no elimination criteria during the study) and for whom assay results were available for antibodies against the study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O4">
            <title>Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="155"/>
                  <measurement group_id="O2" value="152"/>
                  <measurement group_id="O3" value="103"/>
                  <measurement group_id="O4" value="101"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroconverted Subjects Against the A/Indonesia/05/2005 Strains of H5N1 Influenza Disease</title>
            <description>A seroconverted subject was defined as a vaccinee with either a pre-vaccination titer less than (&lt;) 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.
Seroconversion rates against the A/Indonesia/05/2005 (H5N1 VIRUS) strain were tabulated on Days 0,42,182 for all subjects, 192 for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and 364 for GSK1562902A Formulation 1 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/INDO, Day 42 [N=155,152,103,101]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="154"/>
                  <measurement group_id="O2" value="151"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 182 [N=155,152,103,101]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="122"/>
                  <measurement group_id="O2" value="121"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 192 [N=127,0,84,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="127"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 364 [N=151,147,100,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="151"/>
                  <measurement group_id="O2" value="100"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects Against the A/Indonesia/05/2005 and A/Turkey/Turkey/01/2005 Strains of H5N1 Influenza Disease</title>
        <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection.
Seroprotection rates against the A/Indonesia/5/2005 (H5N1 virus) strain, were tabulated 95% CI on Days 0,42,182 for all subjects, 192 for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 -Havrix / Havrix Jr Group and 364 for GSK1562902A Formulation 1 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group.
Seroprotection rates against the A/turkey/Turkey/01/2005 (H5N1 virus) strain, were tabulated on Days 182 and 192.</description>
        <time_frame>At Days 0,42, 182, 192 and 364</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects (i.e., those meeting all eligibility criteria, complying with the procedures and intervals defined in the protocol, with no elimination criteria during the study) and for whom assay results were available for antibodies against the study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O4">
            <title>Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="155"/>
                  <measurement group_id="O2" value="152"/>
                  <measurement group_id="O3" value="103"/>
                  <measurement group_id="O4" value="101"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroprotected Subjects Against the A/Indonesia/05/2005 and A/Turkey/Turkey/01/2005 Strains of H5N1 Influenza Disease</title>
            <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection.
Seroprotection rates against the A/Indonesia/5/2005 (H5N1 virus) strain, were tabulated 95% CI on Days 0,42,182 for all subjects, 192 for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 -Havrix / Havrix Jr Group and 364 for GSK1562902A Formulation 1 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group.
Seroprotection rates against the A/turkey/Turkey/01/2005 (H5N1 virus) strain, were tabulated on Days 182 and 192.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/INDO, Day 0 [N=155,152,103,101]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 42 [N=155,152,103,101]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="154"/>
                  <measurement group_id="O2" value="151"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 182 [N=155,152,103,101]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="125"/>
                  <measurement group_id="O2" value="122"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 192 [N=127,0,84,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="127"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 364 [N=151,147,100,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="151"/>
                  <measurement group_id="O2" value="102"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 182 [N=127,0,84,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="73"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 192 [N=127,0,84,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="127"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="28"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Geometric Increase for Anti-H5N1 Antibody Titers</title>
        <description>MGI against the A/Indonesia/05/2005 (H5N1 VIRUS) strain were tabulated on Days 0,42,182 for all subjects, 192 for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and 364 for GSK1562902A Formulation 1 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group.
MGI against the A/turkey/Turkey/01/2005 (H5N1 virus) strain were tabulated on Days 42, 182 and 364.</description>
        <time_frame>At Days 42, 182, 192 and 364</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects (i.e., those meeting all eligibility criteria, complying with the procedures and intervals defined in the protocol, with no elimination criteria during the study) and for whom assay results were available for antibodies against the study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O4">
            <title>Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="155"/>
                  <measurement group_id="O2" value="152"/>
                  <measurement group_id="O3" value="103"/>
                  <measurement group_id="O4" value="101"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Geometric Increase for Anti-H5N1 Antibody Titers</title>
            <description>MGI against the A/Indonesia/05/2005 (H5N1 VIRUS) strain were tabulated on Days 0,42,182 for all subjects, 192 for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and 364 for GSK1562902A Formulation 1 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group.
MGI against the A/turkey/Turkey/01/2005 (H5N1 virus) strain were tabulated on Days 42, 182 and 364.</description>
            <units>Titer</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>A/INDO, Day 42 [N=155,152,103,101]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="96.9" lower_limit="84.9" upper_limit="110.4"/>
                  <measurement group_id="O2" value="108.4" lower_limit="94.2" upper_limit="124.7"/>
                  <measurement group_id="O3" value="1" lower_limit="1" upper_limit="1.1"/>
                  <measurement group_id="O4" value="1.1" lower_limit="0.9" upper_limit="1.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 182 [N=155,152,103,101]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.1" lower_limit="8.3" upper_limit="10.1"/>
                  <measurement group_id="O2" value="9.8" lower_limit="9" upper_limit="10.8"/>
                  <measurement group_id="O3" value="0.9" lower_limit="0.9" upper_limit="1"/>
                  <measurement group_id="O4" value="1" lower_limit="0.9" upper_limit="1.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 192 [N=127,0,84,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="117.7" lower_limit="103" upper_limit="134.5"/>
                  <measurement group_id="O2" value="NA">MGI against the A/Indonesia/05/2005 (H5N1 VIRUS) strain were tabulated on Day 192 for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group only.</measurement>
                  <measurement group_id="O3" value="1.4" lower_limit="1.2" upper_limit="1.6"/>
                  <measurement group_id="O4" value="NA">MGI against the A/Indonesia/05/2005 (H5N1 VIRUS) strain were tabulated on Day 192 for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group only.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 364 [N=151,147,100,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36.2" lower_limit="32" upper_limit="40.9"/>
                  <measurement group_id="O2" value="7.4" lower_limit="6.7" upper_limit="8.2"/>
                  <measurement group_id="O3" value="1.6" lower_limit="1.4" upper_limit="1.7"/>
                  <measurement group_id="O4" value="NA">MGI against the A/Indonesia/05/2005 (H5N1 VIRUS) strain were tabulated on Day 364 for GSK1562902A Formulation 1 and 2-Havrix/Havrix Jr Group, GSK1562902A Formulation 1-Havrix/Havrix Jr Group and GSK1562902A Formulation 2-Havrix/Havrix Jr Group only.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 42 [N=155,152,103,101]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27.7" lower_limit="24" upper_limit="31.9"/>
                  <measurement group_id="O2" value="33.1" lower_limit="28.6" upper_limit="38.3"/>
                  <measurement group_id="O3" value="1.1" lower_limit="1" upper_limit="1.3"/>
                  <measurement group_id="O4" value="1.2" lower_limit="1.1" upper_limit="1.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 182 [N=155,152,103,101]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.6" lower_limit="5" upper_limit="6.3"/>
                  <measurement group_id="O2" value="6.6" lower_limit="6" upper_limit="7.4"/>
                  <measurement group_id="O3" value="1" lower_limit="0.9" upper_limit="1.1"/>
                  <measurement group_id="O4" value="1" lower_limit="0.9" upper_limit="1.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 364 [N=151,147,100,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31.4" lower_limit="26.9" upper_limit="36.7"/>
                  <measurement group_id="O2" value="5.6" lower_limit="5" upper_limit="6.3"/>
                  <measurement group_id="O3" value="3" lower_limit="2.6" upper_limit="3.4"/>
                  <measurement group_id="O4" value="NA">MGI against the A/turkey/Turkey/01/2005 (H5N1) strain were tabulated on Day 364 for GSK1562902A Formulation 1 and 2-Havrix/Havrix Jr Group, GSK1562902A Formulation 1-Havrix/Havrix Jr Group and GSK1562902A Formulation 2-Havrix/Havrix Jr Group only</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects Against the A/Turkey/Turkey/01/2005 Strains of H5N1 Influenza Disease</title>
        <description>Booster seroconversion rates against the A/turkey/Turkey/01/2005 (H5N1 VIRUS) strain were tabulated on Days 192 and 364.
This outcome concerns solely subjects in the GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</description>
        <time_frame>At Days 192 and 364</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects (i.e., those meeting all eligibility criteria, complying with the procedures and intervals defined in the protocol, with no elimination criteria during the study) and for whom assay results were available for antibodies against the study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="151"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroconverted Subjects Against the A/Turkey/Turkey/01/2005 Strains of H5N1 Influenza Disease</title>
            <description>Booster seroconversion rates against the A/turkey/Turkey/01/2005 (H5N1 VIRUS) strain were tabulated on Days 192 and 364.
This outcome concerns solely subjects in the GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/TURK, Day 192 [N=127,84]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="127"/>
                  <measurement group_id="O2" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 364 [N=151,100]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Booster Factor for Hemagglutination Inhibition (HI) Antibodies Against the A/Turkey/Turkey/01/2005 Strain of H5N1 Influenza Disease</title>
        <description>Boooster factor against the A/turkey/Turkey/01/2005 (H5N1 VIRUS) strain were tabulated 95% CI on Days 192,364. This outcome concerns solely subjects in the GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</description>
        <time_frame>At Days 192 and 364</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects (i.e., those meeting all eligibility criteria, complying with the procedures and intervals defined in the protocol, with no elimination criteria during the study) and for whom assay results were available for antibodies against the study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="151"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Booster Factor for Hemagglutination Inhibition (HI) Antibodies Against the A/Turkey/Turkey/01/2005 Strain of H5N1 Influenza Disease</title>
            <description>Boooster factor against the A/turkey/Turkey/01/2005 (H5N1 VIRUS) strain were tabulated 95% CI on Days 192,364. This outcome concerns solely subjects in the GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</description>
            <units>Titer</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>A/TURK, Day 192 [N=127,84]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18.6" lower_limit="16.3" upper_limit="21.3"/>
                  <measurement group_id="O2" value="4.1" lower_limit="3.3" upper_limit="5.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 364 [N=151,100]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.6" lower_limit="5" upper_limit="6.3"/>
                  <measurement group_id="O2" value="3" lower_limit="2.7" upper_limit="3.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Neutralizing Anti-H5N1 Antibody Titers</title>
        <description>Seropositivity rates against the A/Indonesia/5/2005 (H5N1 virus) strain, were tabulated on Days 0,42,182 for all subjects, 192 for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and 364 for GSK1562902A Formulation 1 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group.
Seropositivity rates against the A/turkey/Turkey/01/2005 (H5N1 virus) strain, were tabulated on Days 0, 42,182, 192 and 364.</description>
        <time_frame>At Days 0, 42, 182 192 and 364</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects (i.e., those meeting all eligibility criteria, complying with the procedures and intervals defined in the protocol, with no elimination criteria during the study) and for whom assay results were available for antibodies against the study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O4">
            <title>Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="151"/>
                  <measurement group_id="O2" value="147"/>
                  <measurement group_id="O3" value="100"/>
                  <measurement group_id="O4" value="102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Neutralizing Anti-H5N1 Antibody Titers</title>
            <description>Seropositivity rates against the A/Indonesia/5/2005 (H5N1 virus) strain, were tabulated on Days 0,42,182 for all subjects, 192 for GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and 364 for GSK1562902A Formulation 1 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group.
Seropositivity rates against the A/turkey/Turkey/01/2005 (H5N1 virus) strain, were tabulated on Days 0, 42,182, 192 and 364.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/INDO, Day 0 [N=149,145,98,99]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO,Day 42 [N=150,146,99,100]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="150"/>
                  <measurement group_id="O2" value="146"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 182 [N=151,147,100,102]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="150"/>
                  <measurement group_id="O2" value="147"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 192 [N=149,0,99,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="149"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="75"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 364 [N=149,147,100,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="149"/>
                  <measurement group_id="O2" value="147"/>
                  <measurement group_id="O3" value="73"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 0, [N=149,145,98,100]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="18"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 42, [N=150,146,98,100]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="150"/>
                  <measurement group_id="O2" value="145"/>
                  <measurement group_id="O3" value="10"/>
                  <measurement group_id="O4" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 182, [N=151,147,100,101]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="150"/>
                  <measurement group_id="O2" value="145"/>
                  <measurement group_id="O3" value="11"/>
                  <measurement group_id="O4" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 192, [N=150,0,100,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="150"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="90"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 364, [N=149,145,98,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="149"/>
                  <measurement group_id="O2" value="145"/>
                  <measurement group_id="O3" value="95"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Vaccine Response Rates (VRR) for H5N1 Neutralizing Antibodies</title>
        <time_frame>At Days 42, 182 192 and 364</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects (i.e., those meeting all eligibility criteria, complying with the procedures and intervals defined in the protocol, with no elimination criteria during the study) and for whom assay results were available for antibodies against the study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O3">
            <title>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O4">
            <title>Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="149"/>
                  <measurement group_id="O2" value="145"/>
                  <measurement group_id="O3" value="98"/>
                  <measurement group_id="O4" value="98"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Vaccine Response Rates (VRR) for H5N1 Neutralizing Antibodies</title>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/INDO,Day 42 [N=149,144,98,98]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="147"/>
                  <measurement group_id="O2" value="142"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 182 [N=149,145,98,98]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="127"/>
                  <measurement group_id="O2" value="115"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 192 [N=147,0,97,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="147"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/INDO, Day 364 [N=148,145,98,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="144"/>
                  <measurement group_id="O2" value="126"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Booster Vaccine Response for H5N1 Neutralizing Antibodies</title>
        <description>This outcome concerns solely subjects in the GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</description>
        <time_frame>At Days 192 and 364</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects (i.e., those meeting all eligibility criteria, complying with the procedures and intervals defined in the protocol, with no elimination criteria during the study) and for whom assay results were available for antibodies against the study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</title>
            <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="150"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Booster Vaccine Response for H5N1 Neutralizing Antibodies</title>
            <description>This outcome concerns solely subjects in the GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group as required by the protocol.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/TURK, Day 192, [N=150,100]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="141"/>
                  <measurement group_id="O2" value="38"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/TURK, Day 364, [N=149,98]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="86"/>
                  <measurement group_id="O2" value="36"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Systematically-assessed symptoms: during the 7 days after each vaccination; unsolicited AEs: within 21 days after each vaccination and from Day 0 to Day 84. SAEs were collected throughout the study from Day 0 to Day 364.</time_frame>
      <desc>Solicited general symptoms were assessed in subjects aged less than 6 years and in subjects aged 6 years and more as required by the protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group</title>
          <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
        </group>
        <group group_id="E2">
          <title>GSK1562902A Formulation 1 - Havrix / Havrix Jr Group</title>
          <description>Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
        </group>
        <group group_id="E3">
          <title>GSK1562902A Formulation 2 - Havrix / Havrix Jr Group</title>
          <description>Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
        </group>
        <group group_id="E4">
          <title>Havrix / Havrix Jr Group</title>
          <description>Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Diarrhoea/vomiting</sub_title>
                <description>AE reported for subjects aged less than 6 years.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <description>AE reported for subjects aged less than 6 years.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Irritability / fussiness</sub_title>
                <description>AE reported for subjects aged less than 6 years.</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <description>AE reported for subjects aged less than 6 years.</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Temperature</sub_title>
                <description>AE reported for subjects aged less than 6 years.</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>AE reported for subjects aged 6 years or more.</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>AE reported for subjects aged 6 years or more.</description>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <description>AE reported for subjects aged 6 years or more.</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>AE reported for subjects aged 6 years or more.</description>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>AE reported for subjects aged 6 years or more.</description>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Temperature</sub_title>
                <description>AE reported for subjects aged 6 years or more.</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>AE reported within 21 days post-vaccination.</description>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>AE reported within 21 days post-vaccination.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>AE reported within 21 days post-vaccination.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>AE reported from Day 0 up to Day 84 post-vaccination.</description>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>AE reported from Day 0 up to Day 84 post-vaccination.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>AE reported from Day 0 up to Day 84 post-vaccination.</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
